Literature DB >> 19377492

Angina: Ivabradine for treatment of stable angina pectoris.

Ranil de Silva, Kim M Fox.   

Abstract

The ASSOCIATE study investigators have reported that the I(f) current inhibitor, ivabradine, is safe, improves exercise performance, and delays the development of ischemia in patients with chronic stable angina beingtreated with atenolol. ivabradine should be considered in the medical management of symptom-limited patients with angina, when heart rate is suboptimally controlled.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19377492     DOI： 10.1038/nrcardio.2009.47

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  15 in total

1.  Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction.

Authors:  Gunnar H Gislason; Jeppe N Rasmussen; Steen Z Abildstrøm; Niels Gadsbøll; Pernille Buch; Jens Friberg; Søren Rasmussen; Lars Køber; Steen Stender; Mette Madsen; Christian Torp-Pedersen
Journal:  Eur Heart J       Date:  2006-01-06       Impact factor: 29.983

2.  Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Centralised European Studies in Angina Research (CESAR) Investigators.

Authors:  C J Knight; K M Fox
Journal:  Am J Cardiol       Date:  1998-01-15       Impact factor: 2.778

3.  Natural history of angina pectoris in the Framingham study. Prognosis and survival.

Authors:  W B Kannel; M Feinleib
Journal:  Am J Cardiol       Date:  1972-02       Impact factor: 2.778

4.  Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.

Authors:  Jean-Claude Tardif; Ian Ford; Michal Tendera; Martial G Bourassa; Kim Fox
Journal:  Eur Heart J       Date:  2005-10-07       Impact factor: 29.983

5.  Exercise heart rate/ST segment relation. Perfect predictor of coronary disease.

Authors:  K M Fox
Journal:  Br Heart J       Date:  1982-10

6.  Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial.

Authors:  Jeffrey S Borer; Kim Fox; Patrice Jaillon; Guy Lerebours
Journal:  Circulation       Date:  2003-02-18       Impact factor: 29.690

7.  ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina).

Authors:  Raymond J Gibbons; Jonathan Abrams; Kanu Chatterjee; Jennifer Daley; Prakash C Deedwania; John S Douglas; T Bruce Ferguson; Stephan D Fihn; Theodore D Fraker; Julius M Gardin; Robert A O'Rourke; Richard C Pasternak; Sankey V Williams
Journal:  J Am Coll Cardiol       Date:  2003-01-01       Impact factor: 24.094

8.  The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group.

Authors:  K M Fox; D Mulcahy; I Findlay; I Ford; H J Dargie
Journal:  Eur Heart J       Date:  1996-01       Impact factor: 29.983

9.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Authors:  Kim Fox; Ian Ford; P Gabriel Steg; Michal Tendera; Roberto Ferrari
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

10.  Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology.

Authors:  Kim Fox; Maria Angeles Alonso Garcia; Diego Ardissino; Pawel Buszman; Paolo G Camici; Filippo Crea; Caroline Daly; Guy De Backer; Paul Hjemdahl; José Lopez-Sendon; Jean Marco; João Morais; John Pepper; Udo Sechtem; Maarten Simoons; Kristian Thygesen; Silvia G Priori; Jean-Jacques Blanc; Andrzej Budaj; John Camm; Veronica Dean; Jaap Deckers; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; João Morais; Ady Osterspey; Juan Tamargo; José L Zamorano
Journal:  Eur Heart J       Date:  2006-05-30       Impact factor: 29.983
View more
  2 in total

Review 1.  The Role of Ivabradine in the Management of Angina Pectoris.

Authors:  Alessandra Giavarini; Ranil de Silva
Journal:  Cardiovasc Drugs Ther       Date:  2016-08       Impact factor: 3.727

2.  Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure.

Authors:  Peter Jirak; Dzeneta Fejzic; Vera Paar; Bernhard Wernly; Rudin Pistulli; Ilonka Rohm; Christian Jung; Uta C Hoppe; P Christian Schulze; Michael Lichtenauer; Atilla Yilmaz; Daniel Kretzschmar
Journal:  Acta Pharmacol Sin       Date:  2017-12-14       Impact factor: 6.150
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.